An Expanded Access Trial for Cancer Patients with Specific Mutations
An investigational drug is being used in an expanded access trial for advanced pancreatic and other cancer patients with specific genetic changes.
Attacking Cancer’s Key Mechanisms to Treat Metastatic Pancreatic Cancer
A clinical trial for patients with metastatic pancreatic cancer uses the new drug SM-88 in combination with other agents, to attack the tumor metabolism.
Safety and Effectiveness of a New Drug for Advanced Pancreatic Cancer
Researchers are testing dose safety and effectiveness of a new drug for pancreatic cancer, in combination with gemcitabine.
Testing a New Approach to Treating Advanced Pancreatic Cancer
Scientists are testing a new drug that is an antagonist of stress hormone receptors, in combination with nab-paclitaxel, for advanced pancreatic cancer.
Standard Chemotherapy Plus Novel Drugs for Advanced Pancreatic Cancer
This trial tests the effectiveness of three different novel drugs, including immunotherapy, added to standard treatment for advanced pancreatic cancer.
Slowing the Spread of Advanced Pancreatic Cancer
Researchers are testing a kinase inhibitor that is used to treat lung diseases, including a type of lung cancer, against pancreatic cancer.
Chemotherapy Plus Minimally Invasive Surgery for Pancreatic Cancer
Researchers want to know if irreversible electroporation (IRE), a minimally invasive surgical technique, makes it easier for chemotherapy to reach pancreatic cancer cells.
Targeted Therapy to Inhibit Connective Tissue Growth in Pancreatic Cancer
Researchers are testing a new antibody, a type of targeted therapy, in combination with standard treatment for pancreatic cancer in a phase III trial.
Testing a Drug that Works Only in the Tumor Microenvironment
Scientists are trying a new type of drug combination that gets activated only in the unique conditions of the tumor microenvironment.
Combining Two Drugs with Different Approaches to Enhance Treatment
A clinical trial combines epigenetic therapy and immunotherapy to make immunotherapy more effective for patients with pancreatic and bile duct cancers.